Member's Email
|
Search
|
Sitemap
|
Contact us
Overview
Vision & Values
Letters from the MD & CEO
Businesses
Evolution
Board of Directors
Corporate Citizenship
Awards & Recognitions
Global Locations
Markets
Overview
India
Overview
Divisions
Strategic Focus
Africa & Middle East
Asia
Russia & CIS
Latin America
Central Eastern Europe
Manufacturing
Facilities
Overview
Nasik – India
Baddi – India
Nalagarh – India
Vysoke Myto – Czech
Sao Paulo – Brazil
Overview
New Chemical Entity
(NCE)
Inflammation
Metabolic Disorders
Pain
Gastro Intestinal
New Biologics Entity
(NBE)
Inflammation
Metabolic Disorder
Research Pipeline
R&D Centres of
Excellence
Overview
Mahape
Switzerland
Oxford
Sinnar
Scientific Advisory Board
Contacts
Financial Results / MD&A
Analyst Presentations
Annual Report
Shareholders Corner
Dividend History
Shareholder Forms/Queries
FAQs
Careers Home
Overview
Awards and Recognitions
Values
Why Glenmark
Reasons to join Glenmark
Glenmark Centre of Learning
Employee Testimonials
Campus Recruitment
Apply
Current Jobs
For Consultants
Apply Online
FAQs
News Releases
Media Library
Profiles
Photo Gallery
Fact Sheet
Untitled Page
Financial Results / MD&A
Investors
Investors
Financial Results / MD&A
Analyst Presentations
Annual Report
Shareholders Corner
FAQs
Last Visited Pages
Financial Results / MD&A
FAQs
Sinnar
Home
>
Investors
> Financial Results / MD&A
Financial Result Sheet
FY 10-11
FY 09-10
FY 08-09
FY 07-08
FY 06-07
Management Discussion & Analysis Report (MD&A)
FY 10-11
FY 09-10
FY 08-09
FY 07-08
FY 06-07
News Room
30 Aug 2010
Glenmark announces the Discovery of a novel chemical entity 'GRC 17536', a potential first-in-class molecule globally
View Financial Results for the year:
Select
2010